Eisai Co., Ltd announced that the latest data on its in-house developed AMPA
receptor antagonist Fycompa® (perampanel hydrate, “perampanel”) will be
presented at the 69th American Epilepsy Society (AES) Annual Meeting to
be held from December 4 to 8 in Philadelphia in the United States.
For this year's AES meeting, poster presentations will be given on 22
abstracts with highlights including additional and pooled analyses on
the results of global Phase III clinical studies on primary generalized
tonic-clonic (PGTC) seizures in patients with generalized epilepsy
(Study 332) and on partial-onset epilepsy (Study 304, Study 305, Study
306), as well as the results of a Phase III clinical study on
partial-onset epilepsy conducted in Asia including Japan. Furthermore,
the overall results of Study 332, Study 304 and Study 306 were published in the major scientific journal Neurology, while the overall results of Study 305 were published in the specialist epilepsy journal Epilepsia.
Perampanel is a first-in-class antiepileptic drug (AED) discovered and
developed by Eisai. With epileptic seizures being primarily mediated by
the neurotransmitter glutamate, the agent is a highly selective,
noncompetitive AMPA receptor antagonist that reduces neuronal
hyperexcitation associated with seizures by targeting glutamate activity
at postsynaptic AMPA receptors.
